DermaBio

Company Overview

Snapshot

Founded in July 2022 by Miriam Oron Ph.D. and Meital Portugal, DermaBio operates with 1–10 employees. The company has secured funding across two rounds, with its Pre-Seed round occurring in April 2025.

Business overview

DermaBio is at the forefront of precision medicine, leveraging AI to analyze skin biomarkers and develop predictive models. The company's core technology combines a proprietary clinical assay with advanced data modeling to forecast patient responses to biologic therapies. This platform aims to optimize treatment outcomes and reduce healthcare costs across various diseases, serving clinicians, patients, and payers in the Digital Healthcare and Medical Decision Support sectors within the broader Health Tech & Life Sciences industry. The company targets markets in North America and Europe.

Company Intelligence Q&A

What is DermaBio's primary focus in healthcare?

DermaBio focuses on AI-based precision medicine, utilizing skin biomarkers and predictive modeling to anticipate patient responses to biologic therapies, aiming to improve treatment efficacy and reduce healthcare costs.

When was DermaBio founded and by whom?

DermaBio was founded in July 2022 by co-founders Miriam Oron Ph.D. (CEO) and Meital Portugal (CTO).

What is DermaBio's most recent funding activity?

This round was one of two funding rounds the company has completed to date.

What markets does DermaBio currently target?

DermaBio targets the North American and European markets with its precision medicine platform.